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Abstract 
 
Estrogenic compounds are an important class of chemicals that have the ability to 
modulate the function of the nuclear hormone receptor, estrogen receptor beta (ERβ). 
These compounds can be found naturally in the environment or chemically synthesized, 
and have been linked to health risks ranging from altered sexual development to breast 
cancer. Previous work in this lab resulted in an Escherichia coli cellular biosensor 
comprised of an engineered protein scaffold with an inserted human ERβ ligand-binding 
domain fused to a thymidylate synthase reporter enzyme. Through growth in thymineless 
media, the human ERβ biosensor can distinguish between estrogen agonists and 
antagonists based on the resulting E. coli growth phenotype. Preliminary results using 
several animal-based ERβ bacterial biosensors (cow, zebrafish, and rat) revealed species-
specific responses to ligands and identified chlorodecone as an ER antagonist and dioctyl 
phthalate and  Bisphenol B as weak ER agonists.  This research sought to extend the ERβ 
biosensor method to include sentinel animal species, such as the zebra finch and wood 
frog, which serve as early indicators of the presence of environmental toxins. Using 
bioinformatics and molecular cloning techniques, novel sentinel species-based ERβ 
biosensors were created and validated against known strong and weak estrogens using the 
high throughput bacterial assay method. Higher sensitivity analogs of four animal 
biosensors were also constructed and exhibited greater than 10-fold increases in ligand 
response sensitivity. Unique responses to weak and strong estrogens were also observed 
for biosensors across a range of vertebrates (mammals, fish, birds, and amphibians), 
suggesting species-specific susceptibility for certain endocrine disruptors with greater 
deviations observed for weaker estrogens. In addition, biosensors selective for TRβ and 
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ERα were constructed, exhibiting the ability of the ERβ biosensor to be easily modified 
for other pharmaceutically relevant nuclear hormone receptors. Adaptation of the ERβ 
biosensor to sentinel species, in particular, will enable the prevention and treatment of 
diseases through early detection of estrogenic compounds in the environment and expand 
the bacterial biosensor library. These animal ERβ bacterial biosensors will also provide a 
broader understanding of how drug response deviates across species in pre-clinical 
development.
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Introduction 
Estrogens are hormones that are involved in critical metabolic pathways found in 
the reproductive, nervous, cardiovascular, bone, and hematopoiesis systems [1]. 
Estrogens can be found naturally in the environment or artificially synthesized, and 
through activation of one of its nuclear hormone receptor subtypes (estrogen receptor 
beta or estrogen receptor alpha), estrogen plays a key role in human development and the 
onset of puberty. However, estrogen-like endocrine disrupting compounds (EEDCs), 
which are primarily synthetic estrogenic compounds, can interfere with the activity of 
natural estrogens due to their structural similarity as seen in Figure 1. Commonly well-
known EEDCs include chemicals such as DDT, dioxins, PCBs (polychlorinated 
biphenyls), BPA, PBBs (polybrominated biphenyls), and phthalate esters [2].   
 
Figure 1: Chemical structure for E2, the native ligand for the estrogen receptor, along with the 
structures of several well-known EEDCS 
One of the most well-known cases of EEDC interference is DES and its impact on 
the female fetuses of mothers who took the drug from 1948 to 1971. These children later 
suffered from reproductive organ dysfunction, immune system disorders, abnormal 
pregnancies, and experienced increased rates of vaginal clear-cell adenocarcinomas as 
young women [3]. In addition to human impacts, estrogenic compounds can also have 
detrimental effects on wildlife as evidenced by studies documenting distorted sex organ 
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development and function in alligators due to pesticide exposure as eggs, DDT-induced 
thinning of eagle egg shells, demasculinization and feminization of fish, birds, and 
mammals, and impaired immune systems in birds and mammals [3,4]. 
Although estrogenic compounds can result in human and animal health risks, 
some can also act as potential pharmaceuticals due to their ability to modulate the activity 
of the estrogen receptor as selective estrogen receptor modulators (SERMs). For 
example, tamoxifen, an estrogen antagonist, is the most commonly prescribed endocrine 
treatment for hormone receptor-positive breast cancer [5]. Furthermore, raloxifene 
(another SERM) and additional hormone therapies have also been approved for the 
prevention and treatment of postmenopausal ostereoporosis, with other SERMs in 
development or in clinical trials [6]. Thus, estrogenic compounds and other endocrine 
disruptors are promising pharmaceutical candidates for nuclear hormone receptor (NHR) 
related diseases. 
However, with the comprehensive cost of drug development and discovery 
estimated at US $1.7 billion per drug, major pharmaceutical companies such as Sanofi 
and Astra-Zeneca are spending exorbitant amounts annually on new drugs [7]. This cost 
is attributed primarily to the high rate of failure of trial compounds throughout the drug 
development process caused by a lack of efficacy. Only 11% of compounds that initiate 
first-in-man studies are successfully registered and approximately 43% of compounds in 
phase III trials and 23% in registration fail [7]. As a result, drug development is time-
consuming, expensive, and difficult for companies, greatly reducing the number of novel 
therapeutics introduced per year.  
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One of the contributors to the high cost and time requirement of drug 
development is the immense number of animal models required during preliminary 
studies. Current models for identifying ligands with the potential to affect NHR function 
involve whole animal or mammalian cell assays as well-established protocols exist for 
rats and mice. A commonly used procedure for assessing estrogenic compounds is the rat 
uterotrophic assay in which 21-22 days old rats are fed three daily doses of the compound 
of interest. The rats are then killed on the fourth day and the absolute uterus weight is 
determined [8]. Procedures for other vertebrates follow a similar model of repeatedly 
exposing the animal to a drug for a specific duration of time and then killing them and 
measuring the growth of sex organs [9]. Many of these models also involve large sample 
sizes of animals, require specialized training for animal handling and care, and take 
weeks in order for the animals to reach the ideal testing age. Thus, while these models are 
the most reliable in the prediction of endocrine disrupting compounds due to the 
complexity of using a living animal, they are also time-consuming, labor-intensive, and 
impractical for high-throughput screening [10]. 
In addition to animal models, pharmaceutical companies also utilize several other 
methods, such as high-throughput screening, focused screening, high-throughput docking 
and pharmacophore-based screening algorithms, and physiological screening to find 
potential hits [11, 12]. High-throughput screening typically involves screening millions of 
compounds in 384- to 1536-well microtiter plates over several weeks using mammalian 
cell lines that express the desired receptor or drug target [11]. Once a library of hits has 
been complied, these compounds are then tested in additional assays to create dose 
response curves and eliminate hits that exhibit non-reversible behavior.  
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Another technique gaining popularity is high-throughput docking and 
pharmacophore-based screening algorithms (virtual screening). Virtual screening consists 
of using computational models to predict binding affinity and enables the ability to test 
compounds that a researcher does not physically possess. Pharmacophore searching 
algorithms and cheminformatics are also performed as complements to high-throughput 
docking, improving computational efficiency through the ability to generate large virtual 
libraries of compounds, perform extensive filtering of the libraries, and automate data 
processing [12]. Thus, through in silico screening techniques, it is possible to easily 
identify small subsets of compounds for testing as compared to screening millions of 
chemicals. Currently though, these techniques are primarily used as an accompaniment to 
bioassays as many commercially available high-throughput docking programs operate 
using a rigid receptor approximation and thus cannot account for the flexibility of the 
protein or ligand in determining a ligand’s binding ability [12]. 
Finding a way to better facilitate pharmaceutical innovation through the creation 
of biomarkers capable of accurately determining compound efficacy in the preliminary 
developmental stages would reduce clinical costs and could lead to an increase in the 
amount of therapeutics introduced for the treatment of diseases. Furthermore, an assay 
that could determine potential endocrine disruptors using bacterial biosensors would 
provide an alternative method to preliminary animal models, decreasing the amount of 
time, money, and animal lives that must be sacrificed during the drug development 
process. A high-throughput assay utilizing bacterial biosensing cells would also be faster 
and cheaper than mammalian cells if it could be shown that the response was comparable 
across both cell systems. In addition, using bacterial biosensors would enable the 
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determination of hits and their dose response curves with only a single assay. Escherichia 
coli is also a well-characterized and simple organism to modify, allowing for facile 
adaptation of the assay for a wide range of drug targets. Finally, development of animal-
based bacterial biosensors will provide a greater understanding of how drug response 
may deviate across species during preclinical trials and can help reduce human and 
wildlife exposure to endocrine disruptors through early detection of these compounds in 
the environment. 
Background 
Nuclear Hormone Receptors 
Nuclear hormone receptors (NHRs) are proteins that act as ligand induced 
transcription factors during gene expression and exist in a wide variety of metazoan 
organisms [13]. NHRs are considered a single superfamily of receptors, but consist of 
multiple subfamilies that are defined based on sequence homology and on dimerization 
and DNA-binding mechanism [14]. For example, subfamily 3 consists of the estrogen 
receptor-like receptors and includes amongst its members, estrogen receptors α and β 
(ERα and ERβ), the glucocorticoid receptor, and the androgen receptor. The NHRs 
consist of different regions with independent functional domains that can be interchanged 
amongst related receptors without any loss of function. All of the receptors are comprised 
of a variable N terminus, a conserved DNA-binding domain (DBD), a linker region, a 
conserved ligand-binding domain (LBD), and a variable C terminus as shown in Figure 2 
on the next page.  
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Figure 2: General schematic of the domains in a nuclear hormone receptor [13] 
Due to the interaction between the DBD and LBD, small molecules can be used to 
control the transcription activity of the NHR. Compounds that have the ability to bind to 
the NHR and activate transcription are termed agonists, while compounds that can inhibit 
agonist-induced responses are called antagonists [10]. As receptors have both an inactive 
and an active state, agonists are able to activate a receptor by driving equilibrium to favor 
the receptor’s active state. Conversely, antagonists block agonist responses by binding to 
the receptor and driving equilibrium to favor the inactive state [15]. Due to their ability to 
regulate a variety of physiological and developmental functions, ranging from 
reproduction to metabolism, nuclear hormone receptor function has been linked to 
various human diseases such as cancer, obesity, and diabetes [16]. Thus, NHRs are an 
important class of protein targets for drug discovery as identifying compounds with the 
ability to modulate the function of these nuclear hormone receptors offers an opportunity 
for the development of new and effective therapeutics.  
Bacterial Biosensor Construction 
Bacterial biosensors are microorganisms that have been engineered to express a 
biosensing protein that binds to a target compound/ligand. The presence of the target 
compound causes a change in the cell’s activity, which can be read through a change in 
growth rate or fluorescence [17]. The E. coli hormone biosensor used as a template for 
the sentinel species-based biosensors consists of an engineered protein scaffold with four 
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unique protein domains: a maltose-binding domain, a cleaving and splicing-deficient 
domain from the Mycobacterium tuberculosis RecA intein (mini-intein), the ligand-
binding domain (LBD) of estrogen receptor beta (ERβ), and a thymidylate synthase (TS) 
reporter enzyme. A schematic of the biosensor can be found in Figure 3 on the next page. 
 
Figure 3: Diagram of the biosensor 
The maltose-binding domain serves to enhance solubility of the fusion protein 
while the mini-intein assists in stabilizing the NHR LBD, as correct folding of nuclear 
hormone receptors has been found to be difficult in E. coli [10]. Finally inclusion of the 
NHR LBD and TS into the biosensor scaffold enables the ability to create a high-
throughput assay for ligand identification by directly coupling E. coli growth to ligand 
binding. 
Biosensor mechanism  
 All of the biosensors were constructed using E. coli D1210ΔthyA, a bacterial 
strain that has the native thymidylate synthase (TS) enzyme function knocked-out [18]. 
Therefore, the bacteria are unable to synthesize thymidine monophosphate (dTMP), and 
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thus cannot create new DNA and replicate in thymineless media.  Usage of the knockout 
strain ensures that any observed bacterial growth in the presence of thymineless media 
must be the result of endogenously synthesized thymine from the activation of the TS 
reporter enzyme located in the biosensor scaffold.  
The thymidylate synthase reporter enzyme is involved in the folate cycle and is 
necessary for DNA synthesis and survival of the cell in the absence of thymine. 
Thymidylate synthase exists as a homodimer and catalyzes the reductive methylation of 
deoxyuridine monophosphate (dUMP) by methylene tetrahydrofolate to produce 
dihydrofolate and dTMP, the precursor to thymine as seen in Figure 4 below [19].  
 
Figure 4: The dTMP cycle [19] 
In the bacterial biosensor, the TS reporter enzyme is fused to both the maltose-
binding domain and the mini-intein, which contains the LBD as seen in Figure 2.  Thus, it 
is hypothesized that in the protein’s natural state, with no ligand bound, the dimerization 
of TS is partially blocked causing low TS activity [10]. When a ligand is bound to the 
ligand binding pocket of the LBD though, it induces a conformational change within the 
protein [13]. Through this conformational change, the LBD can inhibit TS activity by 
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blocking TS dimerization such that even lower activity than the unbound state is 
observed [10]. A ligand can also induce a conformational change in the LBD that allows 
for increased TS activity. Therefore, agonist and antagonist ligands can be determined 
through TS activity level and the resulting growth rate of the cell. 
Methods 
Chemicals and Reagents 
 The estrogen analogs 17 β-estradiol (E2), Estriol (E3), Estrone (E1), 
Diethylstilbestrol (DES), Daidzein (7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-
one), Bisphenol A (4,4'-(propane-2,2-diyl)diphenol; BPA), Bisphenol S (4,4'-
sulfonyldiphenol; BPS), and Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-
benzopyran-4-one) were purchased from Sigma-Aldrich (St. Louis, MO). In addition, 15 
ICCVAM (Interagency Coordinating Committee on the Validation of Alternative 
Methods) recommended compounds were also purchased from Sigma-Aldrich (St. Louis, 
MO) and a list of these compounds can be found in Table 1 below. All compounds were 
dissolved in dimethyl sulfoxide (DMSO) to a final stock concentration of 10 mM and 
stored at -20 °C.  
Table 1: List of the 15 tested ICCVAM recommended compounds 
1,1-Dichloro-2,2-bis(4-chlorophenyl)ethene  Linuron  
Dioctyl phthalate  2,4,5-Trichlorophenoxyacetic acid  
Chlorodecone  3,4-Cumyl phenol  
Spironolactone  6-Propyl-2-thiouracil  
4,4’-(butane-2,2-diyl)diphenol (Bisphenol B) Atrazine  
Cycloheximide  Cyproterone acetate  
Progesterone  Flavone  
 
 The thymineless (–Thy) media used in all of the biosensor tests consisted of 1 mL 
of 0.1 M CaCl2, 200 mL of Minimal Davis Broth (35 mg/mL dipotassium phosphate, 10 
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mg/mL monopotassium phosphate, 2.5 mg/mL sodium citrate, 0.5 mg/mL magnesium 
sulfate, 5 mg/ mL ammonium sulfate), 10 mL of 10% casamino solution, 10 mL of 20% 
glucose, 200 μL of 1% Thiamine HCl, 10 mL of Thy Pool solution (2 mg/mL of each of 
the following: L-Arg, L-His, L-Leu, L-Meth, L-Pro, and L-Thr), 4 mL of 25 mg/mL 
ampicillin and q.s. to 1 L using deionized water. The Minimal Davis Broth and 0.1 M 
CaCl2 were sterilized by autoclaving at 121 °C for 40 minutes and then cooled to room 
temperature. The other stock solutions were sterilized via vacuum filtration using a 0.2 
μm filter. 
Plasmid Construction 
Due to the modular nature of the biosensor and the conservation of the estrogen 
receptor across species, sentinel-species based ERβ sensors could easily be constructed 
through replacement of the human ERβ ligand-binding domain (LBD) with the ERβ LBD 
of each respective species. The putative LBD of each species of interest was determined 
through protein sequence alignments of each animal’s ERβ against human ERβ as seen in 
Figure 5 below.  
  
Figure 5: Protein sequence alignment of ERβ LBDs with the alignment order as follows from the 
top: rat, human, alligator, zebra finch, green anole lizard, and zebrafish. 
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Once the ERβ LBD sequences of the zebrafinch and the American alligator had 
been determined, the corresponding DNA sequences were synthesized from IDT 
technologies (Coralville, IA). In addition, cDNAs of the estrogen receptors of the wood 
frog (L. sylvaticus) and the northern leopard frog (L. pipens) were also obtained. The ERβ 
LBDs of the three sentinel species (zebrafinch, alligator, and wood frog), were then 
cloned using overlap extension PCR into both the standard pMIT vector and the 
pMIT:1GS (more sensitive) vector previously designed and built in the lab. This 
technique was chosen as a more efficient method to avoid the need to subclone the LBDs 
into a shuttle vector such as pGEM and to make the method more generalizable 
regardless of the species. Two pairs of PCR primers (FAgeI/R110; F383/RXhoI) were 
designed and used to amplify the N- and C-terminus intein fragments. The 110_383 
cloning sites were chosen to maintain consistency with the original cloning of 
pMIT::ERβ*(human). After the two intein fragments had been successfully amplified via 
PCR, primers for amplifying the LBDs were designed as this cloning method requires the 
primers to be long enough such that they amplify 20 base pairs of the intein in addition to 
the desired LBD. From there, a final round of PCR was completed to incorporate all three 
PCR fragments into a single unit using the outer-most primers of FAgeI and RXhoI. Q5 
polymerase was also used for all PCR reactions due to its high-fidelity. The resulting 
PCR products, as well as the pMIT vectors, were digested with SgrA1 (a unique 
restriction enzyme site within the intein's N terminal) and XhoI. Ligations were prepared 
at room temperature and Anoue DH5α competent cells were used for the transformations. 
Cloning was confirmed via digest check and PMGF sequencing. 
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High-Throughput 96 –well Plate Biosensor Assay 
 As described in previous work, pMIT::ERβ*(animal) plasmids were transformed 
into the E. coli strain D1210ΔthyA::KanR [  Δ(gpt-proA)62 leuB6 supE44 ara-14 galK2 
lacY1 Δ(mcrC-mrr) rpsL20 (Strr) xyl-5 mtl-1 recA13 lacIq] and selected for on Luria-
Bertani (LB) agar plates supplemented with 200 μg/mL ampicillin and 50 µg/mL 
thymine. Single colonies were chosen and used to inoculate 3 mL LB media liquid 
cultures supplemented with 200 μg/mL ampicillin and 50 µg/mL thymine, and then 
incubated with shaking at 37°C for 14-16 hours. A portion of the overnight cultures (30 
µL) were then used to inoculate fresh 3 mL LB media liquid cultures supplemented with 
200 μg/mL ampicillin and 50 µg/mL thymine. The liquid cultures were incubated and 
shaken at 37°C until an optical density at 600 nm (OD600) of approximately 1.1 -1.3 was 
reached.  
  The LB cultures were then diluted into –Thy media and 198 µL of the diluted 
biosensor cells were dispensed into each well of a 96-well plate. The dilution factor of the 
LB cultures into the –Thy media was specifically adjusted to each biosensing strain to 
account for the strain’s basal growth. These adjusted dilutions, in terms of LB inoculum 
to –Thy media (v/v), were 1:400 for pMIT::ERβ*(pig), 1:800 for all of the 
pMIT::ERβ1GS*(animal) biosensors, and 1:200 for the remaining pMIT::ERβ* (animal) 
biosensors.  
Each ligand of interest was diluted into DMSO in a 96-well plate from a stock 
concentration of 10 mM to a maximum concentration of 0.1 mM and a minimum 
concentration of 2.56E-10 M for a 5-fold serial dilution, and a maximum concentration of 
0.1 mM and a minimum concentration of 1E-12 M for a 10-fold serial dilution. The last 
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column of each serial dilution was pure DMSO to provide a baseline value for biosensor 
growth without ligand added. The ligand was then introduced to the diluted biosensor 
cells by adding 2 µL of each dilution to each well for a total volume of 200 µL of ligand 
and cells per well. Both this step and the distribution of diluted biosensor cells into the 
96-well plate were performed using either a multi-channel pipette or a robotic liquid 
handling station (BioMek, 2000/3000, Beckman Coulter). The plates were then incubated 
with shaking at 34°C for up to 22 hours. The OD600 of each well was measured using a 
UV-vis plate reader (BioTek Synergy2) every two hours starting at 14 hours after initial 
incubation. A schematic of the assay process can be seen in Figure 6 on the next page. 
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Figure 6: Flowsheet of the steps of the high throughput bacterial biosensor assay 
Determination of EC50 and RPTA values 
 The effectiveness and strength of each ligand was determined through calculation 
of its EC50 value, which is the concentration at which 50% of the maximum response is 
achieved [16]. The raw OD600 absorbance data was normalized to a percentage of the 
response of the maximum test concentration after first subtracting the background signal. 
EC50 values were then calculated using an Excel-based program that fit the normalized 
absorbance responses to the Hill equation shown in Equation 1 on the next page where Y 
is defined as the scaled OD600 and X is the log of the ligand concentration. 
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Y = b + 
   
         
      (1)       
The other four parameters (a, b, c, and d) were determined using non-linear regression 
where c is defined as the log of the EC50 value for the ligand and a and b are the highest 
and lowest OD600 values for a single compound respectively. 
The relative estrogenicity of a compound as compared to E2 was also determined 
through calculation of relative pseudotransactivation values (RPTA) where RPTA is 
defined as RPTA = 
    
  
    
        and % RPTA is defined as RPTA x 100% [20]. 
Results 
Determination of estrogen agonists and antagonists 
 In order to test the ability of the animal-based biosensors to detect estrogenic 
compounds, 15 ICCVAM (Interagency Coordinating Committee on the Validation of 
Alternative Methods)-recommended compounds were screened against four different 
animal biosensors consisting of human, two additional mammals (cow and rat), and a fish 
(zebrafish). Each biosensor test consisted of 5 ICCVAM recommended compounds, a 
positive control of E2 (native ligand for ERβ), a negative control of Triac (thyroid 
hormone), and a known weak ER agonist (BPA). Dose-response curves were then 
generated using the OD600 data gathered16-22 hours after ligand introduction and the 
responses of the four animal biosensors against seven compounds can be seen in Figures 
7-10 on the following pages.  
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Figure 7: Dose response curve for ERβ-Human 
 
Figure 8: Dose response curve for ERβ-Cow 
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Figure 9: Dose response curve for ERβ-Rat 
 
Figure 10: Dose response curve for ERβ-Zebrafish 
As seen in Figures 7-10, all of the animals showed a strong agonistic response to 
E2 (aqua curve), which is expected as E2 is the native ligand for ERβ, and an antagonistic 
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response to chlorodecone (dark blue). However, not all of the animals responded to the 
other ligands as evidenced by the difference in response between zebrafish (Figure 10) 
and the mammals (Figures 8-10) to Bisphenol B (magenta) and BPA (dark green). The 
zebrafish ERβ biosensor does not identify the two compounds as having any estrogenic 
activity while the other three mammalian sensors clearly show obvious responses to both 
compounds with Bisphenol B resulting in responses of greater than 40% and BPA 
resulting in responses greater than 30%. Thus, it is likely that weaker estrogenic 
compounds in particular induce species-specific response and that the response may be 
slightly dependent on whether the animal is cold or warm-blooded. A summary of the 
estrogenicity of the 15 ICCVAM compounds tested against the animal biosensors can be 
found in Table 2 on the next page. 
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Table 2: Summary of ICCVAM compound estrogenicity 
Compound ERβ-human ERβ-cow ERβ-rat ERβ-
zebrafish 
1,1-Dichloro-2,2-bis(4-
chlorophenyl)ethene 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Dioctyl phthalate  Weak ER 
agonist 
Not 
estrogenic 
Weak ER 
agonist 
Not 
estrogenic 
Chlorodecone  ER 
antagonist 
ER 
antagonist 
ER 
antagonist 
ER 
antagonist 
Spironolactone  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Bisphenol B  ER agonist ER agonist ER agonist Weak ER 
agonist 
Cycloheximide  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Progesterone  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Linuron  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
2,4,5-
Trichlorophenoxyacetic 
acid  
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
3,4-Cumyl phenol  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
6-Propyl-2-thiouracil  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Atrazine  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Cyproterone acetate  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Flavone  Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
Not 
estrogenic 
 
Out of the 15 compounds, it was found that chlorodecone (kepone) demonstrated 
antagonistic activity in all animals, which is consistent with studies using rats showing 
that chlorodecone inhibits the binding of estradiol to the estrogen receptor in a 
competitive manner [21]. Two other compounds, Bisphenol B and dioctyl phthalate also 
showed weak agonistic behavior using the mammalian sensors, which is supported with 
literature results of phthalate esters being known EEDCs and the fact that Bisphenol B is 
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structurally similar to BPA, another weak agonist [2]. The fact that Bisphenol B and 
chlorodecone induced responses in all of the mammalian biosensors suggests that the 
ERβ biosensors are correctly identifying estrogens as both Bisphenol B and chlorodecone 
were shown to bind the ER receptor in in vitro binding assays [22]. 
Development of new sentinel species-based biosensors 
 Based on initial results using ERβ biosensors for cow, rat, zebrafish, and human, 
it was desired to expand the biosensor library to include sentinel species such as reptiles, 
amphibians, and birds in order to further investigate the dependence of ligand response 
on species. Sentinel species were also of interest due to their ability to serve as early 
indicators of environmental toxins, making them ideal candidates for early detection 
methods.  
The sentinel species-based ERβ biosensors were constructed through replacement 
of the human ERβ LBD with the corresponding animal ERβ LBD to produce 
pMIT::ERβ*(zebra finch) and pMIT::ERβ*(L. sylvaticus) constructs. An alligator ERβ 
biosensor was also constructed, but it was cloned directly into the higher sensitivity 
construct, pMIT::ERB1GS*(alligator). Also, due to the presence of single nucleotide 
polymorphisms in the cDNAs for L. sylvaticus (LS), a total of four L. sylvaticus ERβ 
biosensors were created and are denoted as LS ERβ #2, LS ERβ #4, LS ERβ #5, and LS 
ERβ #6. However, these results will focus only on LS ERβ #2 and its higher sensitivity 
analog as it was found that the SNPs resulted in only silent mutations and had no 
significant effect on ligand response. 
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Following the high throughput bacterial biosensor assay method previously 
described, the sentinel species biosensors were validated against E2 as seen in Figure 11 
on the next page. 
 
Figure 11: Dose response curves for ERβ-zebrafinch, LS ERβ #2, and ERβ-human 
Both ERβ-zebrafinch and LS ERβ #2 were able to respond to E2 as seen in Figure 11 
above, which suggests that the ERβ LBD was successfully cloned. Furthermore, the EC50 
values for E2 with all three animals were found to be very similar (ERβ zebrafinch: 
2.48E-7, ERβ human: 1.64E-7, and ERβ #2 200: 1.85E-7), as expected since E2 is the 
native ligand for ERβ and thus a strong ER agonist. It was also found that a dilution of 
1:200 for ERβ #2 was ideal for future biosensing tests in order to be consistent with the 
basal growth rates of the other animal biosensors. 
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Creation of higher sensitivity biosensors 
 Throughout the course of testing, it was found that several of the biosensors were 
unable to respond (reach saturation) to some of the ligands. Thus, higher sensitivity 
analogs of four animal-based biosensors were created to examine whether the increased 
sensitivity would enable the ligand response to reach saturation. The higher sensitivity 
versions of ERβ-cow, ERβ-zebrafish, ERβ-alligator, and LS ERβ #2 were constructed by 
adding a 1GS linker (5 extra amino acids consisting of 4 glycines and 1 serine) into the 
biosensor as shown in Figure 12 below.  
 
Figure 12: Schematic at the DNA level of the 1GS linker biosensor 
In the 1GS biosensor, the 1GS linker is inserted between the C-terminus of the intein and 
the TS reporter enzyme. The extra five amino acids help to relieve some of the steric 
hinderance experienced by the TS reporter enzyme by distancing it from the rest of the 
biosensor scaffold seen in Figure 3. This allows for an increased basal level of TS activity 
as TS dimerization is less hindered in this configuration. Thus, the sensitivity of the 
biosensor is enhanced as the effect of a confirmation change in the LBD on TS activity is 
amplified. 
 Similar to the original cloning of the animal-based ERβ biosensors, the 1GS 
biosensors were constructed by swapping out the human ERβ LBD in the 
pMIT::ERβ1GS*(human) construct with the desired animal ERβ LBD. The higher 
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sensitivity analogs were then tested against several estrogens and compared to their non 
1GS counterparts as seen in Figures 13 and 14 on the next page.  
 
Figure 13: Dose response curve for ERβ–zebrafish against seven estrogens 
 
Figure 14: Dose response curve for ERβ–zebrafish 1GS against seven estrogens 
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 As seen in Figure 13, ERβ–zebrafish was unable to respond to BPA and BPS, 
which are both weak ER agonists, as evidenced by the lack of saturation in the dose 
response curves. Additionally, the response curves for Daidzein, Genistein, and Estriol 
appear to be just barely reaching saturation even at the highest concentration of 1E-4 M. 
The response levels of the three weakest estrogens, Daidzein, BPS, and BPA are also all 
under 40%, suggesting that the ERβ-zebrafish biosensor is not sensitive enough to 
confidently assess these estrogens. However, in comparing the results of the ERβ–
zebrafish 1GS biosensor tested with the same ligands, there is an obvious and distinct 
improvement in sensitivity with the addition of the 1GS linker. The ERβ–zebrafish 1GS 
biosensor dose response curves in Figure 14 indicate that all of the ligands were able to 
reach saturation and even more surprisingly, the response levels of BPA and BPS were 
increased to above 80% from below 20% and below 40% respectively. This enhancement 
in sensitivity was observed across all animal species and ligands, although the effect was 
not as pronounced for stronger estrogens and mammalian species. Table 3 below shows 
the EC50 values of seven estrogens using the ERβ and ERβ 1GS biosensors of each 
animal. 
Table 3: EC50 values for ERβ and ERβ 1GS biosensors 
 
Addition of the 1GS linker in the zebrafish biosensor resulted in more than 20-
fold increases in sensitivity for every compound except for Daidzein, which experienced 
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only a 5-fold increase. However, with the mammalian-based sensors, the average increase 
in sensitivity was only approximately 2 to 5-fold. As seen in Table 3, the greatest 
increases in sensitivity were observed with the weaker estrogens, regardless of species. 
This was expected though since the 1GS linker was included specifically to amplify the 
effect of weaker estrogens.  
Comparison of ligand response across species 
 Using the sentinel species-based ERβ biosensors and existing animal biosensors, a 
comprehensive screen of nine different estrogens of varying strength was conducted in 
order to understand how ligand response varies across species. All of the ERβ biosensors 
were tested using the high throughput method and RPTA and EC50 values were 
calculated from the resulting dose response curves. A comparison of EC50 values 
normalized to the human response can be seen in Figure 15 on the next page. 
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Figure 15: Comparison of relative EC50 values normalized to the human response 
Figure 15 depicts the relative EC50 values of each compound across each species after 
normalization to the human response such that all of the human responses are equal to 1. 
As seen in Figure 15, the greatest deviations in ligand response occur with the cold-
blooded animals. This difference could be a result of the genetic and metabolic 
differences between the two sets of animals due to the unique environments that each live 
in. Studies have shown that zebrafish have a lower sensitivity to BPA as compared to 
rainbow trout due to the ability of the zebrafish liver to quickly metabolize BPA.  
Differences in estrogen sensitivities have also been attributed to differences in estrogen 
receptor (ER) amino acid structure across species and differential subtype ER tissue 
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distribution [23]. The EC50 values also show that warm-blooded animals tend to response 
similarly to each other while cold-blooded animals tend to respond similarly to other 
cold-blooded animals. Thus, animals that live in the same environment (i.e. on land 
versus in water) may have evolved to have similar responses due to similarities in their 
ER amino acid structures since they likely share common ancestors.  
The EC50 values for cold-blooded animals are also observed to be higher than 
those for warm-blooded animals, suggesting that cold-blooded creatures are less sensitive 
to estrogens in general as compared to warm-blooded creatures. Out of the nine species, 
zebrafish displayed the greatest deviations from human response with its responses to 
four compounds (DES, Genistein, Daidzein, and Estriol) having the highest EC50 values, 
suggesting that it is the least sensitive to these compounds.  It is also interesting to note 
that out of all the species, alligator displayed the greatest sensitivity to the different 
estrogens with the lowest EC50 values for a majority of the estrogens. This can be 
attributed though to the fact that the alligator is a species that experiences temperature-
dependent sex determination and is thus, particularly susceptible to environmental 
perturbations [23].  
Aside from cross-species comparisons, testing of the ERβ biosensors against the 
nine estrogens also enabled direct comparison of the EC50 values determined using the 
bacterial biosensor against ICCVAM’s in vitro ER binding and transcriptional activation 
assays as seen in Table 4 on the next page. 
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Table 4: Comparison of EC50 values using the ERβ biosensor and the ICCVAM in vitro binding 
assay 
Compound Human ERβ bacterial 
biosensor EC50 (µM) 
ICCVAM in vitro assay 
EC50 (µM) 
DES 0.0137 0.0189 
E2 0.349 0.098 
Estrone 1.26 0.630 
Estriol 1.06 34.8 
BPA 6.70 450 
 
As seen in Table 4, the EC50 values found using the ERβ biosensor for E2, DES, 
and Estrone are very similar to the values determined using the ICCVAM in vitro assay 
with only a 2-fold difference for Estrone and a 3-fold difference for E2. However, there is 
a significant difference in EC50 values between the two methods for Estriol and BPA, the 
weakest estrogens of the five. The ERβ biosensor assay method resulted in lower EC50 
values (1.06 and 6.70 µM) for the two compounds as compared to the ICCVAM assay 
(34.8 and 450 µM), suggesting that the ERβ biosensor is more sensitive for weaker 
estrogens. 
 In addition to EC50 values, RPTA values, which can be viewed as a measure of 
the binding affinity of the ligand relative to E2, were also determined. The RPTA values 
for all of the estrogens except Genistein and DES can be found in Figure 16 on the next 
page. Genistein and DES were excluded from this figure as both had RPTA values 
significantly greater than 1 as both were found to have greater binding affinity for ERβ 
than E2. 
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Figure 16: RPTA values of the remaining six estrogens (BPA, BPS, Estrone, Estriol, Diadzein, 
and Bisphenol B) 
As seen in Figure 16, the RPTA values for all of the shown estrogens are lower than 1. 
Thus, all of these compounds bind to the ERβ receptor less strongly as compared to E2, 
making them weaker ER agonists. BPS and BPA were found to have the lowest RPTA 
values, suggesting that these compounds are the weakest ER agonists of the six. This 
effect was also observed across all species, suggesting that the decreased sensitivity to 
these compounds was not a result of differences in the ER amino acid structure across 
various species. Figure 16 also demonstrates how species response greatly deviates with 
weaker estrogens as there is no clear trend observable nor is it possible to determine a 
general ranking of estrogenicity for Daidzein, Estriol, Estrone, and Bisphenol B. Table 5, 
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shown below, displays a ranking of compounds based on RPTA values for each species 
and further emphasizes this point. 
Table 5: Ranking of estrogens by RPTA value for each biosensor 
 
Examination of the RPTA values reveals that strong ER agonists such as DES and 
Genistein induce fairly consistent responses across all species with DES being observed 
to have the highest RPTA values followed by Genistein and E2. The remaining six 
estrogens result in RPTA rankings that greatly vary depending on species, making it 
difficult to rank the compounds in order of estrogen strength. However, it is likely that 
Estrone, Estriol, and Diadzein are the next strongest ER agonists after E2 and that BPA is 
the weakest ER agonist based on their consistency in RPTA rankings across all of the 
various species.  
Adaption to other nuclear hormone receptors 
 In addition to the creation of novel sentinel species-based ERβ biosensors, 
biosensors selective for the thyroid receptor (TRβ) and estrogen receptor alpha (ERα) 
were also studied. Due to the highly conserved nature of nuclear hormone receptors 
across species and the modular design of the bacterial biosensor, L. sylvaticus and L. 
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pipens TRβ bacterial biosensors were also created. The TRβ biosensors were constructed 
similar to how the L. sylvaticus ERβ biosensors were by performing protein sequence 
alignment of the L. sylvaticus and L. pipens TRβ LBDs with the human TRβ LBD. The 
human TRβ LBD in pMIT::TRβ*(human) was then replaced with the L. sylvaticus and L. 
pipens TRβ LBDs via overlap extension PCR to yield pMIT::TRβ*(L. sylvaticus) and 
pMIT::TRβ*(L. pipens). The new TRβ biosensors were then tested with tiratricol (Triac), 
which is a thyroid hormone analog and dose-response curves were produced as shown in 
Figure 17 below. 
 
Figure 17: Dose-response curves of L. sylvaticus (LS), L. pipens (LP), and human TRβ 
biosensors 
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As seen in Figure 17, all of the TRβ biosensors were able to respond to Triac, which is 
expected since Triac is an agonist for the thyroid receptor. There are six different LS and 
LP TRβ biosensors shown due to the existence of SNPs in the cDNAs. All of the frog 
TRβ EC50 values, with the exception of LS TRB #2 were lower than that of human TRβ, 
indicating that the frogs are slightly more sensitive to Triac as compared to human. The 
fact that LS TRB #2 exhibited such a high EC50 value of 68.75E-8 M compared to an 
average of 2.78E-8 M for the other LS sensors and 9.39E-8 M for human could be 
attributed to the existence of a SNP that may have caused an amino acid change in the 
LBD. Overall though, the majority of the frog biosensors responded approximately the 
same to Triac regardless of the species (LS or LP) or the presence of SNPs. 
 It was also desired to create ERα analogs of the animal biosensors to investigate 
the difference in ligand response across the two receptor sub-types as it is known that 
ERα and ERβ are primarily located in different tissues, and thus have different roles in 
development [1]. Thus, cloning of ERα analogs of the ERβ biosensors for L. pipens was 
also performed and pMT::ERα*(L. pipens) sensors were constructed. Although the L. 
pipens ERα biosensors have been verified via digest check and PMGF sequencing, they 
have yet to be validated against a library of known estrogens. 
Conclusion 
 Testing of the cow, rat, zebrafish, and human ERβ bacterial biosensors against a 
library of 15 compounds comprised of estrogen agonists, antagonists, and non-estrogens 
revealed that the ERβ bacterial biosensor high-throughput method is capable of reliably 
detecting estrogenic compounds within 16 -22 hours after ligand introduction. In 
addition, species-specific ligand responses were observed, especially for the weaker 
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estrogens and for cold-blooded animals compared to warm-blooded animals. Out of 15 
ICCVAM recommended compounds, it was found that chlorodecone demonstrated ER 
antagonistic activity, and that two compounds, Bisphenol B and dioctyl phthalate, 
showed weak ER agonistic behavior using the mammalian-based biosensors, which was 
consistent with the results of other studies and ICCVAM’s in vitro ER binding assay 
results. The agonistic effects of the aforementioned two ligands though were found to be 
too weak to be observed using the zebrafish ERβ biosensor. Due to this lack of sensitivity 
in the earlier tests, it will be necessary to re-examine these ligands using the 1GS 
biosensors to verify their estrogenicity and to determine if any additional estrogenic 
compounds were missed during the initial ICCVAM compound screening. 
As a result of the species-dependent responses observed during ICCVAM testing, 
three novel sentinel species-based ERβ bacterial biosensors, pMIT::ERβ1GS*(alligator), 
pMIT::ERβ*(zebra finch), and pMIT::ERβ*(LS) were constructed. These ERβ biosensors 
were validated using known strong and weak estrogen agonists such as DES, Daidzein, 
E2, Genistein, and BPA and it was found that all three biosensors could reliably detect 
most, if not all of the estrogens. In addition, higher sensitivity analogs (denoted as 
pMIT::ERβ1GS*(animal) or ERβ-animal 1GS) were created of the cow, zebrafish, LS 
#2, and alligator ERβ biosensors through the insertion of an additional five amino acids 
(1GS linker) between the C-terminus of the intein and the TS reporter enzyme in the 
biosensor scaffold. The addition of the 1GS linker was found to improve ligand 
sensitivity by anywhere from 1 to about 77-fold depending on the species and ligand. The 
1GS biosensors also enabled determination of EC50 values for compounds such as BPA 
and BPS by improving sensitivity and enabling saturation of the ligand response. Prior to 
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construction of the 1GS biosensors, EC50 values for these compounds could not be 
determined for some animals. In addition to the creation of sentinel species-based ERβ 
biosensors and their higher sensitivity analogs, TRβ and ERα biosensors were also 
constructed for L. sylvaticus and L. pipens. Validation and future testing of the TRβ and 
ERα biosensors against their respective compound libraries though will need to be 
performed to truly assess the ability of the ERβ biosensor method to be adapted to other 
nuclear hormone receptors. 
Through analysis of the EC50 and RPTA values generated from the nine different 
animal-based biosensors, it was found that ligand responses are dependent on the species 
and on the ligand itself. In general, it was observed that cold-blooded animals 
(amphibians and fish) were less sensitive to the estrogens as compared to mammals and 
that like-blooded animals tended to behave similarly. The only exception to these 
observations was discovered to be ERβ-alligator, which can be attributed to the fact that 
alligators are more susceptible to environmental changes than other animals. Analysis of 
the RPTA values was also consistent with the earlier observation that weaker estrogens 
are more prone to deviations in ligand response across various animal species.  
Overall, development and testing of novel animal-based ERβ biosensors revealed 
the strength of the bacterial biosensor method as a fast, inexpensive, and alternative 
process for determining estrogenic compounds. The ERβ bacterial biosensors were able 
to correctly identify Genistein, DES, E2, Daidzein, Estrone, Estriol, and BPA as estrogen 
agonists and provide estimates of relative estrogenicity that were comparable to in vitro 
binding and transcriptional activation assays. Differences in EC50 values between the two 
assays were observed to be less than half an order of magnitude for strong ER agonists 
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(E2, DES, and Estrone), but increased to up to two orders of magnitude for weaker ER 
agonists (BPA and Estriol). In addition, the ERβ bacterial biosensor was able to 
determine ER agonist or antagonist behavior within only 16-22 hours after ligand 
introduction as compared to days or weeks with animals. Furthermore, the ERβ biosensor 
method is easily adaptable to other nuclear hormone receptors and animals through its 
modular construction, enabling the potential to create biosensors selective for any animal 
and NHR desired. Expansion of the ERβ biosensor library to include sentinel species and 
higher sensitivity constructs also provided a broader understanding of how ligand 
response deviates across species and allows for the ability to better prevent human and 
wildlife health risks through early detection of environmental endocrine disruptors.  
Future Work 
 
 Through development and screening of the animal-based bacterial biosensors, it 
was possible to demonstrate the potential of the bacterial biosensor to be used as an 
alternative technology for preliminary drug screening and as a tool to gain a greater 
understanding of species-specific susceptibility to endocrine disruptors. Despite these 
promising results though, much work remains before the bacterial biosensor could truly 
be implemented as a common screening method.  
 As mentioned earlier, some of the preliminary studies using the ERβ biosensors 
were inconclusive due to a lack of sensitivity. Thus, the remainder of the animal-
biosensors (zebrafinch, rat, sole, and pig) will be moved to the 1GS construct in order to 
create higher-sensitivity analogs of every animal-based ERβ biosensor. Once the 1GS 
biosensors have been constructed and validated, a comprehensive screen of the nine 
estrogens will be performed again to obtain a clearer understanding of how ligand 
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response varies with the species and the strength of the ligand. Screening of the 
ICCVAM recommended compounds will also be repeated with the 1GS biosensors to 
identify additional ER agonists and antagonists as prior studies were unable to detect 
some of the weaker ER agonists. 
 In addition to conducting further tests with the 1GS biosensors using larger and 
more diverse compound libraries, adaption of the ERβ biosensor to other 
pharmaceutically relevant nuclear hormone receptors will also be continued in order to 
demonstrate the biosensor’s versatility. TRβ and ERα biosensors have already been 
designed, but these sensors still must be validated and tested. Construction of a 
glucocorticoid biosensor will also be an excellent addition to the biosensor library as the 
glucocorticoid receptor is involved in numerous metabolic and immune response-related 
diseases. Finally, an L. pipens ERβ biosensor will be constructed as well as it would be 
interesting to investigate the differences in ligand response across the two frog species 
since all of our previous work has focused on differences between distinct genera.  
 
 
 
  
37 
 
References 
 
 [1]  O. Imamov, S. Gil-Jin, M. Warner and J.-A. Gustafsson, "Estrogen Receptor beta in 
Health and Disease," Biology of Reproduction, vol. 73, no. 5, pp. 866-871, 2005. 
 
[2]  J. R. Roy, S. Chakraborty and T. R. Chakraborty, "Estrogen-like endocrine 
disrupting chemicals affecting pubery in humans--a review," Medical Science 
Monitor, vol. 15, no. 6, pp. 137-145, 2009. 
 
[3]  T. Colborn, F. S. vom Saal and A. M. Soto, "Developmental Effects of Endocrine-
Disrupting Chemicals on Humans and Wildlife," Environmental Health 
Perspectives, vol. 101, no. 5, pp. 378-384, 1993.  
 
[4]  J. G. Vos, "Health Effects of Endocrine-Disrupting Chemicals on Wildlife, with 
Special Reference to the European Situation," Critical Reviews in Toxicology, vol. 
30, no. 1, pp. 71- 133, 2000. 
 
[5]  V. C. Jordan, "Antiestrogens and Selective Estrogen Receptor Modulators as 
Multifunctional Medicines. 2. Clinical Considerations and New Agents," Journal of 
Medicinal Chemistry, vol. 46, no. 7, pp. 1081- 1111, 2003. 
 
[6]  B. S. Komm and A. A. Chines, "An update on selective estrogen receptor 
modulators for the prevention and treatment of osteoporosis," Maturitas, vol. 71, no. 
3, pp. 221-226, 2012.  
 
[7]  I. Kola, "The State of Innovation in Drug Development," Clinical Pharmacology & 
Therapeutics, vol. 83, no. 2, pp. 227-230, 2008.  
 
[8]  J. Odum et al., "The Rodent Uterotrophic Assay: Critical Protocol Features, Studies 
with Nonyl Phenols, and Comparison with a Yeast Estrogenicity Assay," 
Regulatory Toxicology and Pharmacology, vol. 25, no. 2, pp. 176-188, 1997. 
 
[9]  G. Ankley et al., "Overview of a Workshop of on Screening Methods for Detecting 
Potential (Anti-) Estrogenic/Androgenic Chemicals in Wildlife," Environmental 
Toxicology and Chemistry, vol. 17, no. 1, pp. 68-87, 1998. 
 
[10]  A. R. Gillies, G. Skretas and D. W. Wood, "Engineered Systems for Detection and 
Discovery of Nuclear Hormone-Like Compounds," Biotechnology Progress, vol. 
24, no. 1, pp. 8 - 16, 2008. 
 
[11]  J. Hughes, S. Rees, S. Kalindjian and K. Philpott, "Principles of Early Drug 
Delivery,"    British Journal of Pharmacology, vol. 162, no. 6, pp. 1239-1249, 2011. 
 
38 
 
[12]  C. McInnes, "Virtual Screening Strategies in Drug Discovery," Current Opinion in 
Chemical Biology, vol. 11, no. 5, pp. 494-502, 2007.  
 
[13]  A. Aranda and A. Pascual, "Nuclear hormone receptors and gene expression," 
Physiological Reviews, vol. 81, no. 3, pp. 1269 - 1304, 2001. 
 
[14]  D. J. Mangelsdorf et al., "The Nuclear Receptor Superfamily: The Second Decade," 
Cell, vol. 83, no. 6, pp. 835-839, 1995.   
 
[15]  Merck Sharp & Dohme Corporation, "Drug Action and Pharmacodynamics," 
[Online]. Available: 
http://www.merckvetmanual.com/mvm/pharmacology/pharmacology    
_introduction/drug_action_and_pharmacodynamics.html. [Accessed 13 April 
2015]. 
 
[16]  S. Khan and J. B. Lingrel, "Thematic Minireview Series on Nuclear Receptors in 
Biology and Diseases," The Journal of Biological Chemistry, vol. 285, no. 50, pp. 
38741-38742, 2010. 
 
[17]  I. Gierach and D. W. Wood, "Engineered Nuclear Hormone Receptor-Biosensors 
for Environmental Monitoring and Early Drug Delivery," in Biosensors for Health, 
Environment, and Biosecurity, 2011, pp. 502-526. 
 
[18]  G. Skretas and D. W. Wood, "A Bacterial Biosensor of Endocrine Modulators," 
Journal of Molecular Biology, vol. 349, no. 3, pp. 464 - 474, 2005.  
 
[19]  C. W. Carreras and D. V. Santi, "The Catalytic Mechanism and Structure of 
Thymidylate Synthase," Annual Review of Biochemistry, vol. 64, pp. 721-762, 
1995. 
 
[20]  I. Gierach, K. Shapero, T. W. Eyster and D. W. Wood, "Bacterial Biosensors for 
Evaluating Potential Impacts of Estrogenic Endrocine Disrupting Compounds in 
Multiple Species," Environmental Toxicology, vol. 28, no. 4, pp. 179-189, 2011. 
 
[21]  W. H. Bulger, R. M. Muccitelli and D. Kupfer, "Studies on the Estrogenic Activity 
of Chlorodecone (Kepone) in the Rat: Effects on the Uterine Estrogen Receptor," 
Molecular Pharmacology, vol. 15, no. 3, pp. 515-524, 1979.  
 
[22]  National Institutes of Health, "ICCVAM Evaluation of In Vitro Test Methods for 
Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen 
Receptor Binding and Transcriptional Activation Assays," 30 May 2003. [Online]. 
Available: 
http://ntp.niehs.nih.gov/iccvam/docs/endo_docs/edfinalrpt0503/edfinrpt.pdf. 
39 
 
[Accessed 23 April 2015]. 
 
[23]  D. A. Crain, "An ecological assessment of bisphenol-A: Evidence from comparative 
biology," Reproductive Toxicology, vol. 24, no. 2, pp. 225-239, 2007. 
 
